Compare CII & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CII | SPTX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2004 | 2026 |
| Metric | CII | SPTX |
|---|---|---|
| Price | $24.52 | $21.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 87.1K | ★ 93.1K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.43 | $17.59 |
| 52 Week High | $26.17 | $22.98 |
| Indicator | CII | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 50.62 |
| Support Level | $23.95 | $18.72 |
| Resistance Level | $24.45 | $22.42 |
| Average True Range (ATR) | 0.49 | 1.41 |
| MACD | -0.09 | -0.17 |
| Stochastic Oscillator | 39.37 | 24.21 |
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.